Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

Corporate Information




Other Corporate Information

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced that the company’s shares will be moved to Nasdaq Stockholm’s Mid Cap segment on January 3rd, 2022.

The move from the Small Cap segment is a result of Nasdaq’s annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between EUR 150 million and EUR 1 billion. The move was announced by Nasdaq Stockholm on December 20th, 2021. The company is now taking the step from the Small Cap to the Mid Cap segment after a strong price trend during the year.